Literature DB >> 9042561

The postdischarge risk of venous thromboembolism after hip replacement. The role of prolonged prophylaxis.

D Bergqvist1.   

Abstract

This review deals with the problems of delayed thrombosis after hip arthroplasty and the possible need for prolonged prophylaxis. These problems have been considered key questions in the European Consensus Statement on venous thromboembolism. There are several factors, such as long immobilisation, venous trauma and decreased venous emptying, which all may contribute to the development of late postoperative thrombosis. There are data on frequencies of venous thromboembolism supporting the occurrence of such late complications. In 4 recent studies on prolonged prophylaxis, it was consistently shown that prophylaxis with low molecular weight heparins for 1 month significantly reduced the frequency of deep venous thrombosis compared with conventional prophylaxis during hospitalisation in patients undergoing elective hip arthroplasty.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9042561     DOI: 10.2165/00003495-199600527-00010

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  40 in total

Review 1.  Review of clinical trials of low molecular weight heparins.

Authors:  D Bergqvist
Journal:  Eur J Surg       Date:  1992-02

2.  Regimen for improved effectiveness of intermittent pneumatic compression in deep venous thrombosis prophylaxis.

Authors:  J H Scurr; P D Coleridge-Smith; J H Hasty
Journal:  Surgery       Date:  1987-11       Impact factor: 3.982

3.  Low-dose heparin and deep-vein thrombosis after total hip replacement.

Authors:  P M Mannucci; L E Citterio; N Panajotopoulos
Journal:  Thromb Haemost       Date:  1976-08-31       Impact factor: 5.249

4.  Pulmonary embolism and its prophylaxis following the Charnley total hip replacement.

Authors:  R Johnson; J R Green; J Charnley
Journal:  Clin Orthop Relat Res       Date:  1977       Impact factor: 4.176

5.  Phlebographic findings in venous thrombosis following total hip replacement.

Authors:  P Kälebo; B A Anthmyr; B I Eriksson; B E Zachrisson
Journal:  Acta Radiol       Date:  1990-05       Impact factor: 1.990

Review 6.  Prophylaxis of postoperative thromboembolism with low molecular weight heparins.

Authors:  L N Jørgensen; P Wille-Jørgensen; O Hauch
Journal:  Br J Surg       Date:  1993-06       Impact factor: 6.939

7.  Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis.

Authors:  M T Nurmohamed; F R Rosendaal; H R Büller; E Dekker; D W Hommes; J P Vandenbroucke; E Briët
Journal:  Lancet       Date:  1992-07-18       Impact factor: 79.321

8.  Thrombosis following hip arthroplasty. A study using phlebography and 125I-fibrinogen test.

Authors:  D Bergqvist; R Elvelin; U Eriksson; A Hjelmstedt
Journal:  Acta Orthop Scand       Date:  1976-10

9.  Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement.

Authors:  A Planes; N Vochelle; F Mazas; C Mansat; J Zucman; A Landais; J C Pascariello; D Weill; J Butel
Journal:  Thromb Haemost       Date:  1988-12-22       Impact factor: 5.249

10.  The natural history and aetiology of deep vein thrombosis after total hip replacement.

Authors:  J M Sikorski; W G Hampson; G E Staddon
Journal:  J Bone Joint Surg Br       Date:  1981-08
View more
  2 in total

Review 1.  Risk of post-discharge venous thromboembolism in patients with rheumatoid arthritis undergoing knee or hip arthroplasty. Is prolonged thromboprophylaxis warranted or dangerous?

Authors:  M T Nurmohamed; W F Lems; B A Dijkmans
Journal:  Ann Rheum Dis       Date:  1999-07       Impact factor: 19.103

2.  High Risk of Venous Thromboembolism After Surgery for Long Bone Metastases: A Retrospective Study of 682 Patients.

Authors:  Olivier Q Groot; Paul T Ogink; Stein J Janssen; Nuno Rui Paulino Pereira; Santiago Lozano-Calderon; Kevin Raskin; Francis Hornicek; Joseph H Schwab
Journal:  Clin Orthop Relat Res       Date:  2018-10       Impact factor: 4.176

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.